Talphera price to sales ratio TLPH

Market value divided by revenue over the last twelve months, since 2014.

Today, Oct 23, 2026: n/m; a sliver of sales
Last meaningful: 6.1×; Aug 2023
10-year median: 24.6×
10-year range: 3.2× to 144×
Peer median: 0.9×

Talphera's price to sales ratio is not a meaningful number today: a multiple this high rests on a sliver of sales.

It was last meaningful in Aug 2023, at 6.1×.

On the days it had one over the last ten years, its median was 24.6×, from 3.2× in Mar 2023 to 144× in Apr 2019.

Price to sales ratio over time

median 24.6×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	6.1×	3.2×	12.7×
2022	11.1×	5.0×	17.7×
2021	18.8×	18.5×	44.1×
2020	21.8×	21.8×	66.9×
2019	73.4×	54.4×	144×
2018	63.6×	6.3×	98.6×
2017	7.5×	5.4×	14.9×
2016	9.3×	5.3×	11.6×
2015	35.0×	8.7×	39.7×
2014	9.3×	8.3×	18.3×

Against its peers

Companies in Drug Manufacturers - General nearest Talphera's size, closest first, today.

Company	Price to sales ratio
TLPHTalphera	n/m
SPROSpero Therapeutics	1.4×
ATNMActinium Pharmaceuticals	n/m
LFVNLifevantage	0.4×
NATRNatures Sunshine Products	0.4×
ARVNArvinas	1.5×
Peer median	0.9×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Talphera

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.